Overview

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pfizer